opioid crisis
The company’s device, Primary Relief, is the latest of DyAnsys’ long list of devices to receive FDA clearance.
HIMSS22
In a preview of their HIMSS22 session, Kasey Claborn of the University of Texas and Andrea L. Daugherty from the Dell Medical School explain how better overdose surveillance could improve response and outreach.
The study also found patients in the 24-week group had a 27% decrease in unique hospital encounters compared with the group who only received one prescription.
Flare Capital Partners reviews the current landscape of substance use disorder treatment and highlights some early-stage tech companies tackling the ongoing opioid epidemic.
The company formerly focused its efforts on enabling chronic pain management care.
The company plans to triple its production, design and engineering teams with the new funds.
In the first edition of the HIMSS TV Deep Dive series, doctors, civil servants and entrepreneurs share ways to treat and prevent overuse and addiction.
Dr. James Hellewell, medical director of Care Transformation Information Systems at Intermountain, says we need to look at other ways to treat patients’ pain without exposing them to high-risk medications.
Because telehealth tools enable faster access to care and help emergency clinicians make decisions at the bedside to reduce unnecessary admissions and length of stay, costs are being reduced, says Anton Arbatov, senior director SOC Telemed.
Prescription drug monitoring programs are forcing providers to put data into a state system for use in making informed care decisions, according to New Jersey state officials Shereef Elnahal and Nancy Pinkin.